About BioCopy AG

The startup has developed a biomolecule copying technology that enables the efficient production and replication of microarrays, facilitating research in tumor and autoimmune therapies. This technology simplifies the complex interactions of the immune system, enhancing capabilities in diagnostics, vaccine development, and lead screening.

```xml <problem> The conventional methods of discovering and developing biotherapeutic drugs for cancer are often slow, costly, and carry a risk of failure during the transition from early-stage discovery to industrial-scale production. Existing biotherapeutics may also damage healthy cells, leading to life-threatening side effects. </problem> <solution> BioCopy provides an AI-powered, end-to-end automated platform that accelerates the discovery and development of next-generation biotherapeutics for cancer. The platform leverages precision screening and an automated lab to analyze a multitude of cancer cell markers and potential biotherapeutics, providing early insights into safety and efficacy. By integrating AI and machine learning with proprietary data, BioCopy can predictively design safer and more effective drug candidates, significantly reducing the time and cost associated with traditional drug development processes. The platform's accelerated development process mimics industrial processes, increasing developmental success rates and redefining time-to-market benchmarks. </solution> <features> - AI-driven platform for predictive design of next-generation biotherapeutics - End-to-end automation for high-throughput engineering of multi-specific antibody therapeutics - Precision screening technology (ValidaTe) for large-scale analysis of cancer cell markers and biotherapeutics interactions - Automated lab capable of analyzing up to 25,000 drug candidates in parallel - Proprietary data farms for storing and leveraging drug candidate design data - Focus on internal cancer cell markers for more precise cancer cell binding and reduced risk of damage to healthy cells - Building-block method for combining diverse functional components into a single drug candidate </features> <target_audience> BioCopy's primary customers are pharmaceutical companies seeking to accelerate the development of safer and more effective next-generation biotherapeutics for cancer, as well as researchers in the fields of immunology and oncology. </target_audience> ```

What does BioCopy AG do?

Where is BioCopy AG located?

BioCopy AG is based in Basel, Switzerland.

How much funding has BioCopy AG raised?

BioCopy AG has raised 2180000.

Location

Basel, Switzerland

Funding

2180000

Employees

40 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

BioCopy AG

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

biocopy.com 1K+

Crunchbase

Basel, Switzerland

Funding

Estimated Funding

$2M+

Team (40+)

No team information available.

Company Description

Problem

The conventional methods of discovering and developing biotherapeutic drugs for cancer are often slow, costly, and carry a risk of failure during the transition from early-stage discovery to industrial-scale production. Existing biotherapeutics may also damage healthy cells, leading to life-threatening side effects.

Solution

BioCopy provides an AI-powered, end-to-end automated platform that accelerates the discovery and development of next-generation biotherapeutics for cancer. The platform leverages precision screening and an automated lab to analyze a multitude of cancer cell markers and potential biotherapeutics, providing early insights into safety and efficacy. By integrating AI and machine learning with proprietary data, BioCopy can predictively design safer and more effective drug candidates, significantly reducing the time and cost associated with traditional drug development processes. The platform's accelerated development process mimics industrial processes, increasing developmental success rates and redefining time-to-market benchmarks.

Features

AI-driven platform for predictive design of next-generation biotherapeutics

End-to-end automation for high-throughput engineering of multi-specific antibody therapeutics

Precision screening technology (ValidaTe) for large-scale analysis of cancer cell markers and biotherapeutics interactions

Automated lab capable of analyzing up to 25,000 drug candidates in parallel

Proprietary data farms for storing and leveraging drug candidate design data

Focus on internal cancer cell markers for more precise cancer cell binding and reduced risk of damage to healthy cells

Building-block method for combining diverse functional components into a single drug candidate

Target Audience

BioCopy's primary customers are pharmaceutical companies seeking to accelerate the development of safer and more effective next-generation biotherapeutics for cancer, as well as researchers in the fields of immunology and oncology.